X4 Pharmaceuticals, Inc. (XFOR) Stock

X4 Pharmaceuticals, Inc. (XFOR) is a Healthcare stock trading at $4.20 (as of 2026-06-18), with a market capitalization of $381.05M and a trailing P/E of -2.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare diseases, including mavorixafor, a small-molecule CXCR4 inhibitor in Phase III and Phase Ib clinical trials for multiple conditions. The company also develops CXCR4 antagonists X4P-002 and X4P-003 and licenses mavorixafor for certain oncology combination uses under an agreement with Abbisko Therapeutics.

Valuation — source: SEC EDGAR (first-party)
Price	$4.20
Market Cap	$381.05M
P/E Ratio	-2.0
EV / EBITDA	-2.5
Price / Book	2.26
Price / Sales	47.04
DCF Value (model)	$-17.63
DCF Upside vs Price	-519.8%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.50M
Net Margin	-1218.4%
Return on Equity	-59.2%
Debt / Equity	0.45
Current Ratio	10.18
Revenue Growth (YoY)	154.2%
EPS Growth (YoY)	884.2%
FCF Growth (YoY)	-34.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-3.69 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.0
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-109.3%
vs Industry	-111.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	MORGAN STANLEY ($39.10M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Adam R. Craig
Employees	143
Country	US
IPO Date	2017-11-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by revenue (market cap unavailable); US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.